We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

101 hedge funds and large institutions have $734M invested in Revance Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more call options, than puts

Call options by funds: $944K | Put options by funds: $466K

13% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 110 → 101 (-9)

14% less capital invested

Capital invested by funds: $854M → $734M (-$120M)

40% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 20

Holders
101
Holders Change
-9
Holders Change %
-8.18%
% of All Funds
2.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
12
Increased
34
Reduced
30
Closed
20
Calls
$944K
Puts
$466K
Net Calls
+$478K
Net Calls Change
+$339K

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$9.39M
2
Renaissance Technologies
Renaissance Technologies
New York
+$8.71M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$6.52M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$5.23M
5
JP Morgan Chase
JP Morgan Chase
New York
+$3.49M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.8M
2
Millennium Management
Millennium Management
New York
-$5.27M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.32M
4
EIM
Essex Investment Management
Massachusetts
-$2.17M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$2.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
EIM
101
Essex Investment Management
Massachusetts
– -$2.17M -87,355 Closed
Federated Hermes
102
Federated Hermes
Pennsylvania
– -$2.08M -83,810 Closed
TCM
103
Tekla Capital Management
Massachusetts
– -$1.94M -77,919 Closed
AA
104
ALPS Advisors
Colorado
– -$1.62M -65,366 Closed
WRF
105
Waddell & Reed Financial
Kansas
– -$1.59M -63,900 Closed
Two Sigma Investments
106
Two Sigma Investments
New York
– -$970K -39,039 Closed
Jennison Associates
107
Jennison Associates
New York
– -$864K -34,753 Closed
FAM
108
Fred Alger Management
New York
– -$746K -30,000 Closed
Walleye Trading
109
Walleye Trading
New York
– -$534K -21,501 Closed
Two Sigma Advisers
110
Two Sigma Advisers
New York
– -$472K -19,000 Closed
Susquehanna International Group
111
Susquehanna International Group
Pennsylvania
– -$312K -14,158 Closed
PA
112
Profund Advisors
Maryland
– -$277K -11,144 Closed
SCA
113
Secor Capital Advisors
New York
– -$227K -9,131 Closed
Balyasny Asset Management
114
Balyasny Asset Management
Illinois
– -$205K -8,262 Closed
AQR Capital Management
115
AQR Capital Management
Connecticut
– -$201K -8,086 Closed
QT
116
Quantbot Technologies
New York
– -$84K -3,381 Closed
Simplex Trading
117
Simplex Trading
Illinois
– -$41.8K -1,897 Closed
BNP Paribas Financial Markets
118
BNP Paribas Financial Markets
France
– -$25.7K -1,035 Closed
NIT
119
NumerixS Investment Technologies
British Columbia, Canada
– -$10K -400 Closed
PCM
120
Prelude Capital Management
New York
– -$5K -200 Closed
1 2 3 4
5

RVNC Hedge Fund Activity: Q4 2018 in Review

101 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2018, worth a combined $734M — down 14% from $854M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of RVNC and 12 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 34 added.

The largest buyer was Franklin Resources, adding an estimated $9.39M. The largest seller was Fidelity Investments, cutting an estimated $5.8M.

  • 101 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2018, down from 110 in Q3 2018.
  • Funds reported $734M of Revance Therapeutics, Inc. stock for Q4 2018, down 14% quarter-over-quarter.
  • 12 funds opened new Revance Therapeutics, Inc. positions in Q4 2018 and 20 closed out, a net change of -8 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2018 was Franklin Resources, an estimated $9.39M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2018 was Fidelity Investments, an estimated $5.8M sold.

Based on aggregated 13F filings for Q4 2018.